Pharvaris, a clinical-stage biopharmaceutical company, has announced that it will be presenting clinical data on their novel oral bradykinin B2 receptor antagonists at two upcoming congresses. The abstracts have been accepted for presentation at the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA), which will be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas, scheduled to take place from March 15-17, 2024, in Panama City, Panama.
The presentations at these international conferences will shed light on Pharvaris’ efforts in developing treatments for hereditary angioedema (HAE) attacks. HAE is a rare genetic condition characterized by episodes of swelling in various parts of the body, including the hands, feet, abdomen, and airways. These attacks can be severely debilitating and potentially life-threatening.
Pharvaris specializes in the development of bradykinin B2 receptor antagonists, which are aimed at treating and preventing HAE attacks. Their oral medications offer a convenient and patient-friendly alternative to current therapies, which often involve injections. By blocking the bradykinin B2 receptor, the medications aim to reduce the production and activity of bradykinin, a peptide responsible for triggering the swelling and inflammation associated with HAE attacks.
The clinical data that Pharvaris will be presenting at the congresses will provide further insights into the efficacy and safety of their investigational medications in treating HAE. These presentations offer an important platform for researchers, healthcare professionals, and industry experts to exchange knowledge and discuss the latest advancements in the field of hereditary angioedema.
The 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) in Milan, Italy, will gather experts from the region to discuss the latest developments and advancements in the management of HAE. Pharvaris’ presentation at the conference will contribute to the collective knowledge and support the sharing of best practices in the field.
The 2024 HAE International (HAEi) Regional Conference Americas, to be held in Panama City, Panama, will focus on HAE care and research in the Americas region. Pharvaris’ participation in this conference underscores their commitment to addressing the specific needs and challenges faced by HAE patients in the Americas.
Pharvaris’ clinical data presentations at these congresses not only highlight the progress they have made in their research and development efforts but also demonstrate their dedication to improving the lives of HAE patients worldwide. By developing innovative oral medications, Pharvaris aims to transform the treatment landscape for HAE and provide patients with more convenient and effective therapeutic options.
Comments